Related references
Note: Only part of the references are listed.Systemic Human CR2-Targeted Complement Alternative Pathway Inhibitor Ameliorates Mouse Laser-Induced Choroidal Neovascularization
Baerbel Rohrer et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2012)
Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis
Siranush A. Sargsyan et al.
KIDNEY INTERNATIONAL (2012)
The Benefit of Targeted and Selective Inhibition of the Alternative Complement Pathway for Modulating Autoimmunity and Renal Disease in MRL/lpr Mice
Hideharu Sekine et al.
ARTHRITIS AND RHEUMATISM (2011)
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury
Brandon Renner et al.
KIDNEY INTERNATIONAL (2011)
Pharma interest surges in antibody drug conjugates
Sarah Webb
NATURE BIOTECHNOLOGY (2011)
Genetic Factors Associated with Age-Related Macular Degeneration
Nicolas Leveziel et al.
OPHTHALMOLOGICA (2011)
A Crystal Structure of the Complex Between Human Complement Receptor 2 and Its Ligand C3d
Jean M. H. van den Elsen et al.
SCIENCE (2011)
Mutational Analyses Reveal that the Staphylococcal Immune Evasion Molecule Sbi and Complement Receptor 2 (CR2) Share Overlapping Contact Residues on C3d: Implications for the Controversy Regarding the CR2/C3d Cocrystal Structure
David E. Isenman et al.
JOURNAL OF IMMUNOLOGY (2010)
Delineation of the Complement Receptor Type 2-C3d Complex by Site-Directed Mutagenesis and Molecular Docking
Craig D. Shaw et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Renal Inflammation: Targeted Iron Oxide Nanoparticles for Molecular MR Imaging in Mice
Natalie J. Serkova et al.
RADIOLOGY (2010)
The internal thioester and the covalent binding properties of the complement proteins C3 and C4
S. K. Alex Law et al.
PROTEIN SCIENCE (2010)
Pathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury
Liudmila Kulik et al.
JOURNAL OF IMMUNOLOGY (2009)
Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase
Danielle Paixao-Cavalcante et al.
MOLECULAR IMMUNOLOGY (2009)
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators
Jin Wu et al.
NATURE IMMUNOLOGY (2009)
A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-Related Macular Degeneration
Baerbel Rohrer et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice
Kirsten L. Rose et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Solution Structure of the Complex Formed between Human Complement C3d and Full-length Complement Receptor Type 2
Keying Li et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Molecular Basis of the Interaction between Complement Receptor Type 2 (CR2/CD21) and Epstein-Barr Virus Glycoprotein gp350
Kendra A. Young et al.
JOURNAL OF VIROLOGY (2008)
Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21)
Kendra A. Young et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models
Yongli Li et al.
JOURNAL OF IMMUNOLOGY (2007)
Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development
Liudmila Kulik et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Structure of C3b reveals conformational changes that underlie complement activity
Bert J. C. Janssen et al.
NATURE (2006)
Structure of the Epstein-Barr virus major envelope glycoprotein
Gerda Szakonyi et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Drusen complement components C3a and C5a promote choroidal neovascularization
M Nozaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection
C Atkinson et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: Activation without engagement of an inhibitory signaling pathway
T Lyubchenko et al.
JOURNAL OF IMMUNOLOGY (2005)
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice
JM Thurman et al.
MOLECULAR IMMUNOLOGY (2005)
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice
JM Thurman et al.
JOURNAL OF IMMUNOLOGY (2003)
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration
GS Hageman et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2001)
Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg
JM Guthridge et al.
BIOCHEMISTRY (2001)
Advances in immunology: Complement (Second of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
